Nautilus Biotechnology said applications close today for its Iterative Mapping Grant Program, offering selected researchers early access to the Voyager Platform

Nautilus Biotechnology said applications close today for its Iterative Mapping Grant Program, offering selected researchers early access to the Voyager Platform. The program targets EGFR and AKT1 proteoforms in cancer biology, underscoring Nautilus’ push in proteomics research.